Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lingbo Biotechnology (Hangzhou)

Request full access

Biologic artificial blood vessels for tissue engineering

Hangzhou, ChinaFounded 2019

About Lingbo Biotechnology (Hangzhou)

Lingbo Biotechnology (Hangzhou) Co., Ltd. is a biotechnology firm established in 2019, specializing in the field of tissue-engineered medical devices. The company is focused on the research and development of biologic artificial blood vessels. Its main product under development is the "Skeletal Acellular Vessels" (SAV), a biological artificial blood vessel that is positioned to be a pioneering product of its kind in the Chinese market.

The company was founded by Kong Deling, a professor and doctoral supervisor at the College of Life Sciences at Nankai University. Kong is a recipient of the National Science Fund for Distinguished Young Scholars and leads an innovation team recognized by the Ministry of Education.

Lingbo Biotechnology operates in the medical device sector, specifically targeting the market for artificial organs and organ protection products. The company's business model revolves around the research, development, clinical trials, and eventual production and commercialization of its proprietary medical devices. Since its inception, the company has successfully completed several funding rounds, including a Series A+ round in June 2024 led by Tasly Holding Group, a Series A round in November 2023, a Pre-A round in April 2021, and an angel round in August 2020. These funds are allocated to advance clinical trials for existing products and to support the research and development of new applications, such as artificial blood vessels for cardiac bypass surgery.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
13.3/100
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2024 — — Tasly Capital ↗
SERIES A✓Equity / VC Nov 2023 $14M $55M BGI Co-Win · Tigeryeah Capital · Tailong Investment · Insight Capital ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Lingbo Biotechnology (Hangzhou) website traffic

Latest recorded traffic for Lingbo Biotechnology (Hangzhou) is 160 monthly website visits, down 67.3% over the last three months.

Latest monthly visits160 3-month web change-67.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lingbo Biotechnology (Hangzhou) in the Hangzhou ecosystem

Live from Dealroom

The Lingbo Biotechnology (Hangzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Insight Capital

Series A5 investors entered at this stage

  • Pan-Lin Asset Management
  • BGI Co-Win
  • Tigeryeah Capital
  • Tailong Investment
  • Tasly Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Hangzhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lingbo Biotechnology (Hangzhou) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lingbo Biotechnology (Hangzhou)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.